

TO:

- WADA Accredited Laboratories
- IOC Medical Commission Members
- National Olympic Committees
- NOC Medical Liaison Officers (via relevant NOC)
- International Winter Sports
 Federations on Olympic
 Programme
- Olympic Games Organising Committees
- National Anti-Doping Organisations (via relevant NOC)
- World Anti-Doping Agency

CC:

- Court of Arbitration for Sport
- Association of International Olympic Winter Sports Federations (AIOWF)
- IOC Members

Ref. No CL/ADR/AVY/RBU/2018 By e-mail

PyeongChang, 4 February 2018

IOC Anti-Doping Rules applicable to the Olympic Winter Games PyeongChang 2018

Dear Sir, Madam,

Reference is made to the letter sent to you by the IOC on 4 September 2017, regarding the IOC Anti-Doping Rules applicable to the Olympic Winter Games PyeongChang 2018 (IOC Anti-Doping Rules), which were issued on a provisional basis. In such version of the IOC Anti-Doping Rules, the IOC stated that it may delegate the control and implementation of Doping Control at the Olympic Winter Games PyeongChang 2018, or a part thereof, to an independent testing authority and may issue corresponding new anti-doping rules applicable to Doping Control performed by such authority.

On 5 December 2017, the IOC Executive Board decided to delegate the responsibility for implementing parts of the doping control in connection with the *Olympic Winter Games PyeongChang 2018* to an independent testing authority. In view of such decision, the following amendments to the *IOC Anti-Doping Rules* have been made:

Amendments to the IOC Anti-Doping Rules

- Section 5.3 (Delegation of responsibility, overseeing and monitoring of Doping Control)

A clarification has been made in this section to reflect that part of the anti-doping obligations set forth in the *IOC Anti-Doping Rules have been delegated* to the International Testing Agency (**ITA**) and/or to an *Anti-Doping Organisation*, such as the Global Association of International Sports Federations (**GAISF**).

- Sections 7.1.1.1, 7.2.1, 7.2.4 and 7.2.6

References to the "IOC Medical and Scientific Commission Games Group" have been removed from the text of the *IOC Anti-Doping Rules*.

Section 7.2.4 (Review of Adverse Analytical Findings from Tests Initiated by IOC)

Amendments have been made regarding the list of the *Persons* to be informed in the event of an *Adverse Analytical Finding* which does not reveal a *TUE* or departure from the *International Standards*.

- Section 11.3 (Consequences to Teams in sports which are not Team Sports)

An additional paragraph has been added for *Disqualification* and other related consequences related to curling teams pursuant to the request of the World Curling Federation.

- **Section 17.6** (Amendment and interpretation of Anti-Doping Rules)

An additional sentence related to the interpretation of the *IOC Anti-Doping Rules* in case of inconsistencies and lacunae has been added to the original wording.

Definitions

Additional definitions of the ITA and GAISF, as well as the removal of the definition of "IOC Medical and Scientific Commission Games Group" have been reflected in the definitions section.

Please find attached a copy of the *IOC Anti-Doping Rules*. which are based on the WADA "Model Major Events Organisations Anti-Doping Rules" pursuant to the 2015 World Anti-Doping Code (the *Code*). A copy of these *IOC Anti-Doping Rules*, as well as the *Code* currently in force, can also be found, in English and French, on both the IOC website http://www.olympic.org/medical and the WADA website http://www.wada-ama.org. Please note that all italicised terms contained in this letter shall have the same meaning as in the *IOC Anti-Doping Rules*.

Delegation of Responsibility to GAISF

In accordance with the IOC Executive Board's decision of 5 December 2017, the IOC has delegated the responsibility for implementing parts of the Doping Control in connection with the *Olympic Winter Games PyeongChang 2018* to GAISF. During the period of the *Olympic Winter Games PyeongChang 2018*, GAISF will be responsible for the following:

- Appointing the TUE Committee;
- Approving the Test Distribution Plan and any subsequent changes;
- Coordinating the doping control activities with all involved stakeholders;
- Conducting reviews of Adverse Analytical Findings, Atypical Findings and other Anti-Doping Rule Violations described in the IOC Anti-Doping Rules;
- Notifying Anti-Doping Rule Violations and the decisions of the TUE Committee;
- Instructing the IOC to bring an Anti-Doping Rule Violation before CAS.

Please ensure that the documentation and information referred to in this letter are forwarded to all persons linked to your organisation who have a need to know, particularly to the *Athletes*, coaches and medical personnel.

Yours sincerely,

Anne VAN YSENDYCK Legal Affairs Director Richard BUDGETT Medical and Scientific Director

Enclosed: IOC Anti-Doping Rules applicable to the Olympic Winter Games PyeongChang 2018